Statins for non-cystic fibrosis bronchiectasis  by Feldman, Charles
Comment
www.thelancet.com/respiratory   Vol 2   June 2014 431
Non-cystic ﬁ brosis bronchiectasis is a disorder associated 
with permanent dilatation of proximal cartilage-
containing bronchi; the prevalence of this disorder is 
increasing worldwide.1–3 The pathogenesis of bronchiectasis 
has been described as a vicious circle of events with 
three main components: airway damage, infection, 
and ongoing inﬂ ammation.1,2 The airway inﬂ ammatory 
response is associated with accumulation of various cells 
(eg, neutrophils, lymphocytes, and macrophages) and 
proinﬂ ammatory mediators.1–3 Neutrophilic inﬂ ammation 
can be present even without overt infection, suggesting 
some dysregulation of the innate immune response.4 
Treatment of bronchiectasis is directed at addressing 
the three components of the disease process, and recent 
research has focused on the potential beneﬁ t of various 
anti-inﬂ ammatory therapeutic approaches.1,2,4,5   
Long-term, low-dose macrolide treatment has been 
the most promising anti-inﬂ ammatory strategy, and use 
of these agents in selected patients with bronchiectasis 
is recommended.1,2,4,5 Alternative anti-inﬂ ammatory 
treatments include oral and inhaled corticosteroids, 
oral and inhaled non-steroidal anti-inﬂ ammatory 
drugs, agents targeting speciﬁ c mediators (such as the 
interleukins), and various other novel compounds, but 
with scant evidence of eﬃ  cacy and a paucity of data.1,4,5 
Recent ﬁ ndings suggest that statins could be useful 
in patients with bronchiectasis because of their noted 
anti-inﬂ ammatory and immunomodulatory eﬀ ects,4,6,7 
and at least two clinical studies of atorvastatin are 
ongoing.4 Statins have several modulatory eﬀ ects on 
neutrophils, including decreasing production of reactive 
oxygen species and reduction of neutrophil migration.8 
Furthermore, in people with bronchiectasis, clearance 
of apoptotic cells in the airway is defective, which 
contributes to ongoing airway inﬂ ammation.4,9 Statins 
augment the clearance of apoptotic cells (eﬀ erocytosis) 
both in vivo and in vitro.4,8,10  
In The Lancet Respiratory Medicine, Pallavi Mandal and 
colleagues present the results of a randomised controlled 
trial of atorvastatin in patients with stable bronchiectasis.11 
Patients had clinically signiﬁ cant bronchiectasis, 
conﬁ rmed on chest CT, with cough and sputum 
production in the stable state and two or more chest 
infections in the preceding year. Adults (aged 18–79 years) 
received either atorvastatin 80 mg daily (n=30) or placebo 
(n=30) over a 6-month period. The primary outcome 
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feasibility and impact of interventions. For example, 
in tropical regions the timing of inﬂ uenza epidemics 
is less predictable compared with temperate regions, 
which is problematic for vaccine strain selection and the 
scheduling of immunisation programmes.7 In regions 
where several inﬂ uenza epidemics can occur in a single 
year, the annual (rather than seasonal) rate of infection 
might be higher than in regions that experience only 
one inﬂ uenza season per year. This might aﬀ ect the 
development and maintenance of immunological 
protection against clinically apparent disease and the 
strength of immunological selection pressures acting 
upon the viruses. A direct comparison of data from 
diﬀ erent cohorts would be an invaluable next step 
towards a comprehensive understanding of the global 
epidemiology of inﬂ uenza. 
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was a reduction in cough from baseline to 6 months, 
measured by the Leicester Cough Questionnaire (LCQ) 
score, which the authors had validated previously for use 
in bronchiectasis. Several secondary outcomes were also 
assessed, including statin safety. 
At 6 months, the change in LCQ score from baseline 
diﬀ ered signiﬁ cantly between treatment groups, with 
a mean increase of 1·5 in the statin-treated group 
compared with a mean decrease of 0·7 in the placebo 
group (diﬀ erence 2·2, 95% CI 0·5–3·9; p=0·01); this 
diﬀ erence was also evident at 3 months. When the change 
was analysed as a proportion of improvement in LCQ 
score, the diﬀ erence remained signiﬁ cant (diﬀ erence 23%, 
95% CI 1–45; p=0·04). Other important ﬁ ndings in the 
statin-treated group were an increase in the number of 
apoptotic neutrophils, a decrease in the total number of 
neutrophils in sputum, a reduction in levels of interleukin 
8 in serum, and a mild improvement in the St George’s 
Respiratory Questionnaire (that measures health-related 
quality of life). Ten patients in the statin group had an 
adverse event compared with three in the placebo group 
(diﬀ erence 23%, 95% CI 3–43; p=0·02), without any 
serious adverse events.
This proof-of-concept study is the ﬁ rst to investigate 
the potential beneﬁ t of statins in patients with 
non-cystic ﬁ brosis bronchiectasis. The primary outcome 
measure—a reduction in cough—was achieved, and it is 
an important endpoint because the ﬁ rst recom mendation 
for treatment of patients with bronchiectasis is airway 
clearance.1,2 Concomitant with the reduction in cough 
were improvements in various indices of neutrophilic 
inﬂ ammation, consistent with the known pleotropic 
eﬀ ects of statins.  
The study has several potential limitations; in particular, 
the smoking habits of the two treatment groups diﬀ ered 
signiﬁ cantly, with more patients in the statin group than 
in the placebo group being never-smokers (87% vs 60%). 
The eﬀ ects that this diﬀ erence might have had on the 
study outcomes are diﬃ  cult to ascertain. Furthermore, 
would a diﬀ erence be noted with use of other statin 
agents? Would a lower dose of statin be as eﬀ ective, in 
view of the greater rate of adverse events in the statin-
treated group? If statins are judged eﬀ ective for patients 
with bronchiectasis, when should treatment be initiated? 
Although a better understanding of the likely role 
of statins in patients with bronchiectasis awaits larger 
multicentre studies, these ﬁ ndings provide a glimmer 
of hope that we might soon have an eﬀ ective anti-
inﬂ ammatory treatment for patients with bronchiectasis.
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Prevention of invasive pneumococcal disease: new evidence 
The ﬁ rst pneumococcal conjugate vaccine PCV7, 
containing seven serotypes (4, 6B, 9V, 14, 18C, 19F, 
and 23F) conjugated to the protein carrier CRM197, was 
introduced more than 13 years ago. After its introduction 
into national paediatric immunisation programmes 
globally, substantial reductions in invasive pneumococcal 
disease, pneumonia, and otitis media have been reported 
with near elimination of disease caused by the seven 
vaccine serotypes. Expansion of serotypes included in 
PCVs became a priority for further prevention of disease. 
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